Sun Pharma

Thus far in the calendar year 2026, Sun Pharma outperformed the market and remained flat, as compared to a 14.7% decline in the BSE Sensex.

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening. The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore. The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures. Separately, the company announced that Gautam Doshi has resigned as a Non-Executive, Independent Director with immediate effect, citing personal reasons. Consequent upon his resignation, he has also ceased to hold positions on

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach

MUMBAI, Sept 29 (Reuters) - India's Sun Pharmaceutical Industries is planning to raise around 100 ​billion rupees ($1.04 billion) via a upee-denominated debt sale ​to partly fund a bridge loan it took to acquire ‌US healthcare firm Organon & Co., three sources said on Tuesday.

Sun Pharma will commercialise and manufacture LIB Therapeutics' once-monthly cholesterol drug outside the US and China after its EU approval

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries -- India's largest pharmaceutical company -- over the proposed USD 11.75-billion acquisition of US-based Organon & Co. S&P Global Ratings assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's Ratings assigned a 'Baa1' long-term issuer rating to the Indian pharmaceutical major. Both agencies have maintained a 'stable' outlook for the company. Baa1 and BBB+ are investment-grade credit ratings that indicate adequate payment capacity with moderate credit risk. The rating actions follow Sun Pharma's binding bid in April 2026 to acquire a 100 per cent stake in Organon for an enterprise value of USD 11.75 billion. The transaction is expected to close by March 2027, subject to regulatory approvals. According to S&P, the acquisition will bolster Sun Pharma's business position, almost doubling its revenue base to about Rs 1.3 trillion (around USD 14 billion) ..

Sun Pharmaceutical Industries on Tuesday announced it has entered into an agreement with the US government to prioritise access to affordable medicines for American patients. As part of the agreement, signed during a ceremony at the White House, Mumbai-based Sun Pharma, India's largest drugmaker, will extend 'Most Favoured Nation' (MFN) pricing to state Medicaid programmes, the company said in a regulatory filing on Tuesday. The commitment to MFN pricing will also apply to Sun Pharma's future innovative medicine launches in the US market, the filing said. MFN pricing generally ensures that a buyer receives the lowest price available for a drug. The agreement, which was signed alongside several other pharmaceutical companies, recognises Sun Pharma's investment in the US by delaying Section 232 tariffs on its innovative pharmaceutical products for over two years. The company did not disclose other terms of the deal. "The United States is a key area of investment and expansion for Su

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Revenue from operations grew 10.5 per cent to ₹15,299.88 crore, while EBITDA margin narrowed by 220 basis points to 28.9 per cent as India sales rose 16 per cent

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

Sun Pharma outlook: Analysts at Bajaj Broking flag a breakout above the monthly consolidation zone and the formation of higher-highs, higher-lows among key reasons for a bullish view on the stock.

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

The Supreme Court allowed Intas Pharmaceuticals to market its cancer drug as Bevatas, rejecting Sun Pharma's plea while removing adverse observations against the company

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Sun Pharma has secured South Africa's approval for its generic semaglutide injection and plans to launch the once-weekly diabetes treatment in the coming days